Biological Markers
Biomarker Data’s Potential to Expedite Approval of Edgewise’s Dystrophy Drug
Biomarkers, drug development, Edgewise Therapeutics, Becker muscular dystrophy, regulatory approval
Alto Neuroscience’s Mid-Stage Depression Trial Fails, Casting Doubts on Neuropsychiatry R&D Strategy
Alto Neuroscience, depression trial, neuropsychiatry R&D, ALTO-100, biomarker strategy, clinical failure
FDA Advisory Panel Rejects PD-1 Inhibitors for Gastric and Esophageal Cancers with Low PD-L1 Expression
FDA, PD-1 inhibitors, gastric cancer, esophageal cancer, PD-L1 expression, biomarker, oncology, drug approval
AstraZeneca Refines NSCLC Treatment Strategies with Biomarker-Driven Approaches
NSCLC, biomarkers, targeted therapy, immunotherapy, AstraZeneca, lung cancer treatment
Director/Vice President of Translational Research: Leading the Bridge from Discovery to Clinical Development
Translational Research, Biomarker Discovery, Preclinical Development, Early Clinical Development, Drug Molecule Development, Translational Science Leadership, Biomarker Development, Target Engagement Strategies, Assay Development (PK/ PD/ Immunogenicity), Clinical Trial Design, Endpoint and Biomarker Strategy, Team Building and Leadership, Cross-Functional Collaboration, Regulatory Approvals
Limited Role for Immuno-Oncology Despite Record Sales at Bavarian Nordic
Bavarian, Biological Markers